Should I buy or sell CASI Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CASI shares. View CASI analyst ratings or view top-rated stocks .

What is CASI Pharmaceuticals' stock price target for 2024?

1 brokerages have issued twelve-month price objectives for CASI Pharmaceuticals' stock. Their CASI share price targets range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 435.7% from the stock's current price. View analysts price targets for CASI or view top-rated stocks among Wall Street analysts .

How have CASI shares performed in 2024?

CASI Pharmaceuticals' stock was trading at $7.16 at the start of the year. Since then, CASI shares have decreased by 68.7% and is now trading at $2.24. View the best growth stocks for 2024 here .

Are investors shorting CASI Pharmaceuticals?

CASI Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 82,200 shares, a decrease of 35.4% from the March 15th total of 127,300 shares. Based on an average daily trading volume, of 198,700 shares, the days-to-cover ratio is presently 0.4 days. Approximately 1.3% of the shares of the stock are short sold. View CASI Pharmaceuticals' Short Interest .

When is CASI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our CASI earnings forecast .

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its quarterly earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.27. The biotechnology company had revenue of $9.82 million for the quarter, compared to analyst estimates of $10.09 million. CASI Pharmaceuticals had a negative net margin of 79.30% and a negative trailing twelve-month return on equity of 77.55%.

When did CASI Pharmaceuticals' stock split?

CASI Pharmaceuticals shares reverse split on the morning of Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA) , OPKO Health (OPK) , Caladrius Biosciences (CLBS) , Overstock.com (OSTK) , Riot Platforms (RIOT) , Boeing (BA) , Enphase Energy (ENPH) , Catalyst Pharmaceuticals (CPRX) , Pure Storage (PSTG) and QUALCOMM (QCOM) .

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CASI

CASI Pharmaceuticals (CASI) Stock Price, News & Analysis

→ The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad)

Free CASI Stock Alerts

$2.24

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.14
▼
$2.36
50-Day Range: $2.24
▼
$6.24
52-Week Range: $1.85
▼
$8.48

Volume: 90,569 shs
Average Volume: 178,325 shs
Market Capitalization: $30.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

Get CASI Pharmaceuticals alerts:

CASI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 435.7% Upside
$12.00 Price Target
Short Interest: Healthy
1.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.50
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.69 out of 5 stars

Medical Sector

229th out of 919 stocks

Pharmaceutical Preparations Industry

88th out of 406 stocks

3.5

Analyst's Opinion

Consensus Rating
CASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
CASI Pharmaceuticals has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.31% of the float of CASI Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
CASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in CASI Pharmaceuticals has recently decreased by 35.43%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
CASI Pharmaceuticals does not currently pay a dividend.
Dividend Growth
CASI Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CASI Pharmaceuticals has received a 62.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Melphalan" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for CASI Pharmaceuticals is -1.50.

0.0

News and Social Media Coverage

Search Interest
Only 2 people have searched for CASI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 22.23% of the stock of CASI Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of CASI Pharmaceuticals is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CASI Pharmaceuticals is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CASI Pharmaceuticals has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About CASI Pharmaceuticals Stock (NASDAQ:CASI)

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CASI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CASI Stock News Headlines

April 10, 2024 | investing.com

CASI Pharmaceuticals updates on Juventas dispute

April 8, 2024 | finance.yahoo.com

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 28, 2024 | benzinga.com

Recap: CASI Pharmaceuticals Q4 Earnings

March 28, 2024 | markets.businessinsider.com

CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023

March 28, 2024 | finance.yahoo.com

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

March 18, 2024 | finanznachrichten.de

Aptevo Therapeutics: Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

March 16, 2024 | finance.yahoo.com

CASI Apr 2024 2.500 call

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 11, 2024 | markets.businessinsider.com

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

March 8, 2024 | msn.com

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers

March 7, 2024 | finance.yahoo.com

CASI Mar 2024 10.000 call

March 7, 2024 | finance.yahoo.com

CASI Mar 2024 7.500 put

March 5, 2024 | msn.com

CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients

March 5, 2024 | msn.com

CASI stock rises on positive interim data from early stage trial for its NHL treatment in China

March 5, 2024 | marketwatch.com

CASI Pharma Shares Soar After Positive Preliminary Trial Data for Cancer Immunotherapy

March 5, 2024 | prnewswire.com

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

February 20, 2024 | msn.com

CASI begins dosing lymphoma patients with pralatrexate in China

February 18, 2024 | msn.com

CASI Pharmaceuticals Reveals Business and Financial Updates Quarter 2024

February 16, 2024 | finance.yahoo.com

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

February 16, 2024 | prnewswire.com

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

February 13, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: CymaBay Therapeutics (CBAY), G1 Therapeutics (GTHX) and Gritstone Oncology (GRTS)

January 31, 2024 | es-us.finanzas.yahoo.com

Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer

January 3, 2024 | finance.yahoo.com

Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer

December 28, 2023 | benzinga.com

CASI Pharmaceuticals Stock (NASDAQ:CASI) Dividends: History, Yield and Dates

December 18, 2023 | finance.yahoo.com

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Price Is Right But Growth Is Lacking After Shares Rocket 33%

December 16, 2023 | morningstar.com

CASI Pharmaceuticals Inc CASI

See More Headlines

Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/11/2023
Today: 4/18/2024
Next Earnings (Estimated): 5/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CASI
CUSIP: N/A
CIK: 895051
Web: www.casipharmaceuticals.com
Phone: 861065086063
Fax: 301-315-2437
Employees: 176
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.00
High Stock Price Target: $12.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +435.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-26,940,000.00
Net Margins: -79.30%
Pretax Margin: -77.61%
Return on Equity: -77.55%
Return on Assets: -30.64%

Debt

Debt-to-Equity Ratio: 0.78
Current Ratio: 3.55
Quick Ratio: 2.60

Sales & Book Value

Annual Sales: $33.88 million
Price / Sales: 0.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.81 per share
Price / Book: 1.24

Miscellaneous

Outstanding Shares: 13,400,000
Free Float: 10,555,000
Market Cap: $30.02 million
Optionable: Optionable
Beta: N/A

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Wei-Wu He Ph.D. (Age 59)
Chairman & CEO
Comp: $565.36k
Dr. Wei Zhang Ph.D. (Age 64)
President
Comp: $1.13M
Dr. Alexander A. Zukiwski M.D. (Age 67)
Executive VP & Chief Medical Officer
Comp: $514.79k
Ms. Kun Qian (Age 42)
VP & Global Controller
Ms. Chunhua Wang (Age 52)
Chief Operating Officer
Ms. Wei Gao (Age 43)
General Counsel
Dr. James E. Goldschmidt Ph.D.
Chief Business Development Officer
Mr. Hai Huang (Age 55)
Global Chief Commercial Officer
Ms. Amanda Cui
VP & Global Controller

Key Competitors

View All Competitors

Institutional Ownership

Citadel Advisors LLC
Bought 1,300 shares on 2/15/2024
Ownership: 0.000%

View All Institutional Transactions

CASI Stock Analysis - Frequently Asked Questions

Should I buy or sell CASI Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CASI shares.
View CASI analyst ratings or view top-rated stocks.
What is CASI Pharmaceuticals' stock price target for 2024?: 1 brokerages have issued twelve-month price objectives for CASI Pharmaceuticals' stock. Their CASI share price targets range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 435.7% from the stock's current price.
View analysts price targets for CASI or view top-rated stocks among Wall Street analysts.
How have CASI shares performed in 2024?: CASI Pharmaceuticals' stock was trading at $7.16 at the start of the year. Since then, CASI shares have decreased by 68.7% and is now trading at $2.24.
View the best growth stocks for 2024 here.
Are investors shorting CASI Pharmaceuticals?: CASI Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 82,200 shares, a decrease of 35.4% from the March 15th total of 127,300 shares. Based on an average daily trading volume, of 198,700 shares, the days-to-cover ratio is presently 0.4 days. Approximately 1.3% of the shares of the stock are short sold.
View CASI Pharmaceuticals' Short Interest.
When is CASI Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024.
View our CASI earnings forecast.

How were CASI Pharmaceuticals' earnings last quarter?: CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its quarterly earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.27. The biotechnology company had revenue of $9.82 million for the quarter, compared to analyst estimates of $10.09 million. CASI Pharmaceuticals had a negative net margin of 79.30% and a negative trailing twelve-month return on equity of 77.55%.
When did CASI Pharmaceuticals' stock split?: CASI Pharmaceuticals shares reverse split on the morning of Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of CASI Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).
How do I buy shares of CASI Pharmaceuticals?: Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CASI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial